0913693 B.c.(OTC) REPCF

Market Cap$7.00K

Since IPO (2010)-100%

5 Year-100%

1 Year-95%

1 Month+0%

$0.00

+0.00%

+0.00Today

0913693 B.c. last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-06-23

0913693 B.c. stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-04-06
1 month	+0%	USD 0.00	2026-04-06
3 month	+0%	USD 0.00	2026-03-18
Year to date	+0%	USD 0.00	2025-11-06
1 year	-95%	USD 0.00	2025-05-19
3 year	-99.91%	USD 0.12	2023-06-23
5 year	-99.97%	USD 0.33	2021-06-24
Since inception	-100%	USD 15.50	2010-12-23

0913693 B.c. Financials at a Glance

Market Cap

$7.00K

Revenue (TTM)

CA$530.58K

Net Income (TTM)

CA$7.73M

EPS (TTM)

-$0.08

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-145.57 (Low)

Dividend

$0.00

Beta (Volatility)

-145.57 (Low)

Price

$0.00

Volume

1,455

Open

$0.00

Price

$0.00

Volume

1,455

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 4, 2025

Dividend

$0.00

Beta (Volatility)

-145.57 (Low)

Price

$0.00

Volume

1,455

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 4, 2025

REPCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 0913693 B.c.

RepliCel Life Sciences Inc. is a biotechnology firm based in Vancouver, Canada, specializing in regenerative medicine. The company focuses on developing patient-specific cell therapies to address functional cellular deficits.

Products and Services

RCT-01 targets chronic tendinosis
RCS-01 treats aging and sun-damaged skin
RCH-01 aims to alleviate hair loss

Growth Outlook

Key partnerships with YOFOTO and Shiseido enhance research capabilities
Innovative device RCI-02 for dermal injections is in development
Collaboration with the University of British Columbia for hair follicle research

Financial Highlights

Recent quarterly revenue of 88,471 CAD shows stability
Trailing twelve months (TTM) revenue of 353,445 CAD indicates growth potential
Operating income margin improved to 62% in Q2 2026

RepliCel Life Sciences Inc. is positioned in the biotechnology sector, focusing on innovative therapies that leverage the body's own cells. The company has developed a robust pipeline of products aimed at addressing significant health issues, including chronic tendinosis, skin aging, and hair loss. With strategic partnerships and ongoing research initiatives, RepliCel is poised for future growth. Recent financial performance reflects a stable revenue stream, and the company is actively working to enhance its market presence through innovative solutions and collaborations.

AI Generated • Aug 27, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Andrew Schutte

Website

www.replicel.com

Headquarters

Vancouver, BC V6C 3P1, CA

REPCF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-101.77%

Net Income Margin

-27.50%

Return on Equity

1.86%

Return on Capital

N/A

Return on Assets

-33.81%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.00K

Shares Outstanding

70.00M

Volume

1.46K

Avg. Volume

22.734

Financials (TTM)

Gross Profit

CA$176.87K

Operating Income

CA$545.45K

EBITDA

CA$536.84K

Operating Cash Flow

-CA$135.62K

Capital Expenditure

CA$8.30

Free Cash Flow

-CA$135.61K

Cash & ST Invst.

CA$5.50K

Total Debt

CA$1.12M

0913693 B.c. Performance Analysis

0913693 B.c. annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 271,716	-3.7%
2023	2023-12-31	CAD 262,087	-3.5%
2024	2024-12-31	CAD 258,209	-1.5%
2025	2025-12-31	CAD 253,158	-2.0%

0913693 B.c. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	-74.9%
Q2	2026-06-30	-0.2%

0913693 B.c. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.02	-84.9%
2023	2023-12-31	CAD -0.00	-74.2%
2024	2024-12-31	CAD -0.00	-71.8%
2025	2025-12-31	CAD -0.00	272.7%

0913693 B.c. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	100.0%
Q4	2025-12-31	N/A
Q1	2026-03-31	-100.6%
Q2	2026-06-30	-42.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

CA$88.47K

N/A

Gross Profit

CA$88.43K

N/A

Gross Margin

99.96%

N/A

Market Cap

$7.00K

N/A

Market Cap/Employee

$7.00K

N/A

Employees

N/A

Net Income

-CA$71.60K

-149.9%

EBITDA

CA$54.89K

+354.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

CA$5.50K

-63.8%

Total Debt

CA$1.12M

+17.4%

Accounts Receivable

CA$39.09K

+3922.4%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$1.12M

+25.7%

Return on Assets

-33.81%

N/A

Return on Invested Capital

23.46%

N/A

Free Cash Flow

-CA$44.83K

+49.2%

Operating Cash Flow

-CA$44.83K

+49.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RGRXRegeneRx Biopharmaceuticals, Inc.

RGRXRegeneRx Biopharmaceuticals, Inc.$0.00+0.00%

JAGXJaguar Health, Inc.

JAGXJaguar Health, Inc.$0.60-14.06%

PKTXProtoKinetix, Incorporated

PKTXProtoKinetix, Incorporated$0.00+0.00%

SRBCFSirona Biochem Corp.

SRBCFSirona Biochem Corp.$0.01+0.00%

RVXCFResverlogix Corp.

RVXCFResverlogix Corp.$0.07+0.00%

REPLReplimune Group, Inc.

REPLReplimune Group, Inc.$15.04-1.64%

EXELExelixis, Inc.

EXELExelixis, Inc.$59.01-0.20%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.15-0.12%

NVDANvidia

NVDANvidia$230.36+0.01%

PATHUiPath

PATHUiPath$15.19-0.17%

INTCIntel

INTCIntel$95.80+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.13+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.74-0.02%

TSLATesla

TSLATesla$354.08-0.06%

Questions About REPCF

What is the current price of 0913693 B.c.?

0913693 B.c. is trading at $0.00 per share.

What is the 52-week range for 0913693 B.c.?

Over the past 52 weeks, 0913693 B.c. has traded between $0.00 and $0.00.

How much debt does 0913693 B.c. have?

As of the most recent reporting period, 0913693 B.c. reported total debt of CA$792.36K.

How much cash does 0913693 B.c. have on hand?

0913693 B.c. reported CA$3.88K in cash and cash equivalents in its most recent financial results.

What is 0913693 B.c.’s dividend yield?

0913693 B.c. does not currently have a dividend yield.

0913693 B.c.(OTC) REPCF

0913693 B.c. Financials at a Glance

REPCF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About 0913693 B.c.

REPCF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

0913693 B.c. Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About REPCF

What is the current price of 0913693 B.c.?

What is the 52-week range for 0913693 B.c.?

How much debt does 0913693 B.c. have?

How much cash does 0913693 B.c. have on hand?

What is 0913693 B.c.’s dividend yield?

Premium Investing Services